Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-05
2010-06-22
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000, C514S602000, C548S484000, C549S052000
Reexamination Certificate
active
07741362
ABSTRACT:
The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.
REFERENCES:
patent: 4485101 (1984-11-01), Coy et al.
patent: 5409894 (1995-04-01), Handley
patent: 6124256 (2000-09-01), Hayry et al.
patent: 6221870 (2001-04-01), Pfaeffli et al.
patent: 6221888 (2001-04-01), Durette et al.
patent: 6271252 (2001-08-01), Chang et al.
patent: 6329389 (2001-12-01), Suzuki et al.
patent: 6352982 (2002-03-01), Mabuchi et al.
patent: 0 183 271 (1986-06-01), None
patent: WO 97/03054 (1997-01-01), None
patent: WO 97/14715 (1997-04-01), None
patent: WO 97/43278 (1997-11-01), None
patent: WO 97/47317 (1997-12-01), None
patent: WO 98/53818 (1998-12-01), None
patent: WO 02/24192 (2002-03-01), None
patent: WO 03/026575 (2003-04-01), None
Bonini, J.A. et al., “Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF,”Journal of Biological Chemistry275(50): 39324-39331 (Dec. 2000).
Reubi, J.C. et al., “A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors,”European Journal of Phamacology345: 103-110 (1998).
Reubi, J.C. et al., “Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands,”European Journal of Nuclear Medicine28(7): 836-846 (Jul. 2001).
Rivier, J.E. et al., “Potent Somatostatin Undecapeptide Agonists Selective for Somatostatin Receptor 1 (sst1),”Journal of Medicinal Chemistry44(13): 2238-2246 (2001).
Sinisi, A.A. et al., “Different Expression Patterns of Somatostatin Receptor Subtypes in Cultured Epithelial Cells from Human Normal Prostate and Prostate Cancer,”Journal of Clinical Endocrinology and Metabolism82(8): 2566-2569 (1997).
von Essen, R. et al., “Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty: Results of the VERAS Study,”Circulation96(5): 1482-1487 (Sep. 1997).
Yang, H.-Y.T. et al., “Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine,”Proc. National Academy of Science USA82: 7757-7761 (Nov. 1985).
Hoyer, D. et al., “Classification and nomenclature of somatostatin receptors,”TiPS16: 86-88 (Mar. 1995).
Mazarguil, H. et al, “Structure-activity relationships of neuropeptide FF: role of C-terminal regions,”Peptides22: 1471-1478 (2001).
Mori, M. et al., “Differential expression of somatostatin receptors in the rat eye: SSTR4 is intensely expressed in the iris/ciliary body,”Neuroscience Letters223: 185-188 (1997).
Patel, Y.C., “Somatostatin and Its Receptor Family,”Frontiers in Neuroendocrinology20: 157-198 (1999).
Payza, K. et al., “Neuropeptide FF Receptors: Structure-Activity Relationship and Effect of Morphine,”Journal of Pharmacology and Experimental Therapeutics267(1): 88-94 (1993).
Reisine, T. et al., “Molecular Biology of Somatostatin Receptors,”Endocrine Reviews16(4): 427-442 (Aug. 1995).
Bourguignon, J.J. et al., “Analogs of NPFF, a neuropeptide which modulates morphine analgesia,”Proceedings of the XIVth International Symposium on Medicinal Chemistry, pp. 35-44 (1997) (Elsevier Science B.V.).
Brussaard, A.B. et al., “Peripheral Injection of DNS-Injection RFa, A FMRFa Agonist, Suppresses Morphine-Induced Analgesia in Rats,”Peptides10: 735-739 (1989).
Cheng, Y.-C. et al., “Relationship between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction,”Biochemical Pharmacology22: 3099-3108 (1973).
Curtis, S.B. et al., “Somatostatin receptor subtype expression and function in human vascular tissue,”Am. J. Physiol. Heart Circ. Physiol. 278: H1815-H1822 (2000).
Eriksen, U.H. et al., “Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty,”American Heart Journal130(1): 1-8 (Jul. 1995).
Gicquel, S. et al., “Structure-Activity Study of Neuropeptide FF: Contribution of N-Terminal Regions to Affinity and Activity,”Journal of Medicinal Chemistry37(21): 3477-3481 (1994).
Rohrer, S.P. et al., “Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinatorial Chemistry,”Science282: 737-740 (Oct. 1998).
Aavik, E. et al., “Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist,”FASEB Journal16: 724-726 (May 2002).
Bito, H. et al., “Functional Coupling of SSTR4, a Major Hippocampal Somatostatin Receptor, to Adenylate Cyclase Inhibition, Arachidonate Release, and Activation of the Mitogen-activated Protein Kinase Cascade,”Journal of Biological Chemistry269(17): 12722-12730 (Apr. 1994).
Engstrom Mia
Hautamaki Paivi
Hoffren Anna-Marja
Salo Harri
Tauber Andrei
Cordero Garcia Marcel M
Gupta Anish
Oliff & Berridg,e PLC
Siegfried Wurster
LandOfFree
Somatostatin receptor 1 and/or 4 selective agonists and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Somatostatin receptor 1 and/or 4 selective agonists and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin receptor 1 and/or 4 selective agonists and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200156